title: The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.
abstract: Cefpirome, cefoperazone and ceftazidime were tested for their in-vitro activity against Enterococcus faecalis and methicillin-resistant Staphylococcus aureus (MRSA) isolates. Cefpirome was the most active cephalosporin followed by cefoperazone. Ceftazidime had only very limited activity against these strains. In experiments with cefpirome/vancomycin and cefoperazone/vancomycin combinations, synergy was detected against most MRSA strains and some enterococci. Antagonism did not occur.
authors.affiliation: Hoechst AG, SBU Anti-infectives Research, Frankfurt, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Seibert
authors.forename: D
authors.initials: D
authors.lastname: Isert
authors.forename: N
authors.initials: N
authors.lastname: Klesel
authors.forename: M
authors.initials: M
authors.lastname: Limbert
authors.forename: A
authors.initials: A
authors.lastname: Markus
authors.forename: E
authors.initials: E
authors.lastname: Schrinner
mesh_terms: D002438:Cefoperazone / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology; D016983:Enterococcus / Q000187:drug effects*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology*; D000097572:Cefpirome
chemical_list: D002438:Cefoperazone; D002511:Cephalosporins; D014640:Vancomycin; D000097572:Cefpirome